Inovio Pharmaceuticals
104 hedge funds and large institutions have $20.7M invested in Inovio Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 29 closing their positions.
1,384% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $94K
5% less funds holding
Funds holding: 109 → 104 (-5)
9.36% less ownership
Funds ownership: 37.09% → 27.73% (-9.4%)
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
21% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 29
63% less capital inflows, than outflows
Capital inflows: $3.67M | Capital outflows: $10M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$665K |
| 2 |
Renaissance Technologies
New York
|
+$541K |
| 3 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$329K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$324K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
+$313K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.41M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
-$2.18M |
| 3 |
Stonepine Capital Management
Bend,
Oregon
|
-$845K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$784K |
| 5 |
State Street
Boston,
Massachusetts
|
-$748K |
INO Hedge Fund Activity: Q2 2025 in Review
104 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2025, worth a combined $20.7M — down 6.6% from $22.2M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of INO and 24 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 23 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $665K. The largest seller was BlackRock, cutting an estimated $3.41M.
- 104 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2025, down from 109 in Q1 2025.
- Funds reported $20.7M of Inovio Pharmaceuticals stock for Q2 2025, down 6.6% quarter-over-quarter.
- 24 funds opened new Inovio Pharmaceuticals positions in Q2 2025 and 29 closed out, a net change of -5 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2025 was Millennium Management, an estimated $665K added.
- The largest Inovio Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $3.41M sold.
Based on aggregated 13F filings for Q2 2025.